Every Form 4 that Medicinova (MNOV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MNOV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MNOV filings page.
MediciNova Inc. director Nagao Hideki received a grant of 44,500 stock options for Common Stock. The options have an exercise price of $1.36 per share and expire on June 22, 2036. Following this grant, Nagao holds 44,500 stock options directly.
The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the company. This is a compensation-related award rather than an open-market purchase or sale.
MediciNova Inc. director Nicole Lemerond received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $1.36 per share and expire on June 22, 2036. They vest in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, contingent on her continued service with the company.
MediciNova Inc. director Carolyn Beaver received a stock option grant covering 44,500 shares of common stock. The options have an exercise price of $1.36 per share and expire on June 22, 2036. The award vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, subject to her continued service with the company. After this grant, she holds 44,500 derivative securities (options). This is a compensation-related award rather than an open-market share purchase or sale.
MediciNova Inc.'s Chief Medical Officer, Matsuda Kazuko, reported a performance-based equity award on Form 4. On January 16, 2026, the officer acquired an employee stock option to buy 350,000 shares of common stock at an exercise price of $2.10 per share, expiring on January 6, 2035. According to the disclosure, this option was originally granted on January 7, 2025 and was tied to performance criteria for the fiscal year ended December 31, 2025. Those criteria were met, resulting in full vesting of the 350,000-share option, which is now directly owned and fully exercisable.
MediciNova Inc. reported an insider equity award for its President and CEO, Yuichi Iwaki. On January 16, 2026, he acquired an employee stock option covering 450,000 shares of common stock at a $2.10 exercise price per share. These options were originally granted on January 7, 2025 and were tied to performance criteria for the fiscal year ended December 31, 2025. The filing states that the 2025 performance criteria were met, resulting in the full vesting of the option. After this transaction, Iwaki holds 450,000 derivative securities directly, with the options exercisable from January 16, 2026 and expiring on January 6, 2035.